Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21342879 | 0.90 | TMPRSS2 (0.41) | HPRT1ALDH1A1TMPRSS2TNK2RIPK1 | |
| SCHEMBL17719236 | 0.90 | TMPRSS2 (0.41) | HPRT1ALDH1A1TMPRSS2TNK2RIPK1 | |
| SCHEMBL22342703 | 0.90 | TMPRSS2 (0.41) | HPRT1ALDH1A1TMPRSS2TNK2RIPK1 | |
| SCHEMBL30001635 | 0.90 | TMPRSS2 (0.41) | HPRT1ALDH1A1TMPRSS2TNK2RIPK1 | |
| SCHEMBL20078711 | 0.90 | TMPRSS2 (0.33) | TMPRSS2RIPK1 | |
| SCHEMBL881479 | 0.89 | TMPRSS2 (0.36) | HPRT1ALDH1A1TMPRSS2RIPK1 | |
| SCHEMBL21283650 | 0.85 | CYP3A4 (0.33) | TMPRSS2RIPK1 | |
| SCHEMBL20078697 | 0.85 | ADCY2 (0.35) | RIPK1 | |
| SCHEMBL20078705 | 0.85 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL12465034 | 0.85 | CYP3A4 (0.34) | HPRT1ALDH1A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | HPRT1 61/4885ALDH1A1 579/4885TMPRSS2 6/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | HPRT1 61/4885ALDH1A1 579/4885TMPRSS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.